Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) EBT (2020 - 2025)

Roivant Sciences' EBT history spans 6 years, with the latest figure at -$290.4 million for Q4 2025.

  • For Q4 2025, EBT fell 23.82% year-over-year to -$290.4 million; the TTM value through Dec 2025 reached -$953.2 million, down 120.39%, while the annual FY2025 figure was -$681.6 million, 114.92% down from the prior year.
  • EBT reached -$290.4 million in Q4 2025 per ROIV's latest filing, down from -$159.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $5.2 billion in Q4 2023 to a low of -$382.1 million in Q4 2022.
  • Average EBT over 5 years is $114.1 million, with a median of -$241.4 million recorded in 2023.
  • Peak YoY movement for EBT: tumbled 1394.75% in 2021, then surged 1448.82% in 2023.
  • A 5-year view of EBT shows it stood at -$306.0 million in 2021, then dropped by 24.84% to -$382.1 million in 2022, then soared by 1448.82% to $5.2 billion in 2023, then crashed by 104.55% to -$234.5 million in 2024, then decreased by 23.82% to -$290.4 million in 2025.
  • Per Business Quant, the three most recent readings for ROIV's EBT are -$290.4 million (Q4 2025), -$159.0 million (Q3 2025), and -$269.3 million (Q2 2025).